These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 15208748)

  • 1. Discontinuation of risperidone and reversibility of weight gain in children with disruptive behavior disorders.
    Lindsay RL; Leone S; Aman MG
    Clin Pediatr (Phila); 2004 Jun; 43(5):437-44. PubMed ID: 15208748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risperidone-associated weight gain in children and adolescents: a retrospective chart review.
    Martin A; Landau J; Leebens P; Ulizio K; Cicchetti D; Scahill L; Leckman JF
    J Child Adolesc Psychopharmacol; 2000; 10(4):259-68. PubMed ID: 11191686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term effects of risperidone in children with autism spectrum disorders: a placebo discontinuation study.
    Troost PW; Lahuis BE; Steenhuis MP; Ketelaars CE; Buitelaar JK; van Engeland H; Scahill L; Minderaa RB; Hoekstra PJ
    J Am Acad Child Adolesc Psychiatry; 2005 Nov; 44(11):1137-44. PubMed ID: 16239862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Weight-Change Trajectories of Pediatric Outpatients Treated with Risperidone or Aripiprazole in a Naturalistic Setting.
    Pozzi M; Pisano S; Marano G; Carnovale C; Bravaccio C; Rafaniello C; Capuano A; Rossi F; Rizzo R; Bernardini R; Nobile M; Molteni M; Clementi E; Biganzoli E; Radice S
    J Child Adolesc Psychopharmacol; 2019 Mar; 29(2):133-140. PubMed ID: 30452281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Iron homeostasis during risperidone treatment in children and adolescents.
    Calarge CA; Ziegler EE; Del Castillo N; Aman M; McDougle CJ; Scahill L; McCracken JT; Arnold LE
    J Clin Psychiatry; 2015 Nov; 76(11):1500-5. PubMed ID: 26301448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tolerability, Safety, and Benefits of Risperidone in Children and Adolescents with Autism: 21-Month Follow-up After 8-Week Placebo-Controlled Trial.
    Aman M; Rettiganti M; Nagaraja HN; Hollway JA; McCracken J; McDougle CJ; Tierney E; Scahill L; Arnold LE; Hellings J; Posey DJ; Swiezy NB; Ghuman J; Grados M; Shah B; Vitiello B
    J Child Adolesc Psychopharmacol; 2015 Aug; 25(6):482-93. PubMed ID: 26262903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A case series of eight aggressive young children treated with risperidone.
    Cesena M; Gonzalez-Heydrich J; Szigethy E; Kohlenberg TM; DeMaso DR
    J Child Adolesc Psychopharmacol; 2002; 12(4):337-45. PubMed ID: 12625994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treating disruptive behavior disorders with risperidone: a 1-year, open-label safety study in children and adolescents.
    Haas M; Karcher K; Pandina GJ
    J Child Adolesc Psychopharmacol; 2008 Aug; 18(4):337-45. PubMed ID: 18759643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Weight gain in adolescents treated with risperidone and conventional antipsychotics over six months.
    Kelly DL; Conley RR; Love RC; Horn DS; Ushchak CM
    J Child Adolesc Psychopharmacol; 1998; 8(3):151-9. PubMed ID: 9853689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Weight Gain and Metabolic Consequences of Risperidone in Young Children With Autism Spectrum Disorder.
    Scahill L; Jeon S; Boorin SJ; McDougle CJ; Aman MG; Dziura J; McCracken JT; Caprio S; Arnold LE; Nicol G; Deng Y; Challa SA; Vitiello B
    J Am Acad Child Adolesc Psychiatry; 2016 May; 55(5):415-23. PubMed ID: 27126856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effectiveness of risperidone in the treatment of three children with feeding disorders.
    Berger-Gross P; Coletti DJ; Hirschkorn K; Terranova E; Simpser EF
    J Child Adolesc Psychopharmacol; 2004; 14(4):621-7. PubMed ID: 15662156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risperidone-associated steatohepatitis and excessive weight-gain.
    Holtmann M; Kopf D; Mayer M; Bechtinger E; Schmidt MH
    Pharmacopsychiatry; 2003 Sep; 36(5):206-7. PubMed ID: 14571356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months.
    Research Units on Pediatric Psychopharmacology Autism Network
    Am J Psychiatry; 2005 Jul; 162(7):1361-9. PubMed ID: 15994720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: findings of a randomized clinical trial in a drug-naïve population.
    Perez-Iglesias R; Crespo-Facorro B; Martinez-Garcia O; Ramirez-Bonilla ML; Alvarez-Jimenez M; Pelayo-Teran JM; Garcia-Unzueta MT; Amado JA; Vazquez-Barquero JL
    Schizophr Res; 2008 Feb; 99(1-3):13-22. PubMed ID: 18053689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-dependent acute excessive weight gain and metabolic changes in a drug-naive patient on risperidone are reversible with discontinuation: a case report.
    Sahoo S; Mishra B; Akhtar S
    Br J Clin Pharmacol; 2007 Nov; 64(5):715-6. PubMed ID: 17509037
    [No Abstract]   [Full Text] [Related]  

  • 16. Excessive weight gain after remission of depression in a schizophrenic patient treated with risperidone: case report.
    Theleritis CG; Papadimitriou GN; Papageorgiou CC; Dikeos DG; Masdrakis V; Kostoulas C; Psarros C; Soldatos CR
    BMC Psychiatry; 2006 Sep; 6():37. PubMed ID: 16953883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antipsychotic-induced body weight gain: predictors and a systematic categorization of the long-term weight course.
    Gebhardt S; Haberhausen M; Heinzel-Gutenbrunner M; Gebhardt N; Remschmidt H; Krieg JC; Hebebrand J; Theisen FM
    J Psychiatr Res; 2009 Mar; 43(6):620-6. PubMed ID: 19110264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tolerability and safety profile of risperidone in a sample of children and adolescents.
    Margari L; Matera E; Craig F; Petruzzelli MG; Palmieri VO; Pastore A; Margari F
    Int Clin Psychopharmacol; 2013 Jul; 28(4):177-83. PubMed ID: 23689836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of behavior disorders in mental retardation: report on transitioning to atypical antipsychotics, with an emphasis on risperidone.
    Aman MG; Gharabawi GM;
    J Clin Psychiatry; 2004 Sep; 65(9):1197-210. PubMed ID: 15367046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Weight gain with risperidone among patients with mental retardation: effect of calorie restriction.
    Cohen S; Glazewski R; Khan S; Khan A
    J Clin Psychiatry; 2001 Feb; 62(2):114-6. PubMed ID: 11247096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.